Tivic Health Announces Pricing of $4.0 Million Public Offering

SAN FRANCISCO, May 9, 2024–(BUSINESS WIRE)–Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health technology company that develops and commercializes bioelectronic medicines, today announced the pricing of its tender offer for a total of 4,710 000 common shares, Series A warrants to purchase up to 4,710,000 common shares and Series B warrants to purchase up to 7,065,000 common shares, at a public offering price of 0, $85 per share and associated warrants. The Series A Warrants will have an exercise price of $0.85 per share, are immediately exercisable and will expire one year from the date of issuance, and the Series B Warrants will have an exercise price of $0.85 per share, may be exercised immediately and expires five years after the date of issue. The offering is expected to close on or about May 13, 2024, subject to customary closing conditions.

Maxim Group LLC is acting as sole placement agent for the offering.

The aggregate gross proceeds of the offering to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.0 million.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-278383), which was declared effective by the Securities and Exchange Commission (the “SEC”) on May 9, 2024 The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at Electronic copies of the final prospectus, when available, may be obtained from the SEC’s website at and may also be obtained by contacting Maxim Group LLC at 300 Park Avenue , 16th Floor, New York, NY 10022. , by telephone at (212) 895-3745 or by e-mail at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction wherein such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Tivic Health

Tivic Health is a commercial health technology company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation of the trigeminal, sympathetic and vagus nerve structures. Tivic Health’s non-invasive, targeted approach to treating chronic inflammatory diseases offers consumers and providers drug-free therapeutic solutions with high safety profiles, low risk and broad applications. ClearUP, Tivic Health’s first commercial product, is an award-winning, FDA-approved, portable bioelectronic sinus device. ClearUP is clinically proven, recommended by doctors and is available through online retailers and commercial distributors.

Forward-looking statements:

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current beliefs and assumptions regarding future events regarding our business, including statements regarding our plans, assumptions, expectations, beliefs and objectives regarding the achievement of the offering, the satisfaction of customary closing conditions relating to the offering, the intended use of the proceeds of the offering, product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities, market and other conditions and other statements of a predictive nature. These statements are generally identified by the use of words such as “may”, “could”, “should”, “would”, “believes”, “anticipates”, “forecasts”, “estimates”, “expects” “, ” to the intention of “. ,”, “plan”, “continue”, “outlook”, “will”, “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the SEC, including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC. SEC in March. 25, 2024 and the preliminary prospectus filed with the SEC in connection with the public offering. All forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required. by the law.

View source version on


Media Contact:
Morgane Luc
[email protected]

Investor contact:
Hanover International, Inc.
[email protected]